top of page
Browse by category
Search
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
Bariatric surgery induces changes in taste perception, desire and enjoyment of flavours
The majority of participants experience changes in taste perception, desire, and enjoyment of flavours after undergoing sleeve...
Hanmi claims HM17321 is a 'game-changer' in overcoming GLP-1-associated muscle loss
Hanmi Pharm has announced promising research results for its novel obesity treatment, HM17321. According to the company, this...
Journal Watch 6/11/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Omada survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals
Omada Health has released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers...
Cytoki Pharma doses first patient in Phase 2 study of CK-0045 for obesity and T2DM
Cytoki Pharma has announced the first patient has received CK-0045 in a Phase 2 proof-of-concept trial evaluating efficacy, safety and...
Browse by tag
bottom of page